FDA OKs Blueprint/Roche's Gavreto As Rival To Lilly's Retevmo
US Launch For RET Drug Within A Week
Regulators in the US have approved Gavreto for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo.
You may also be interested in...
Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40; New Analgesic Products Make It Past US FDA
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.